<DOC>
	<DOCNO>NCT01404585</DOCNO>
	<brief_summary>The purpose study ass whether BMS-817399 combination Methotrexate effective treat moderate severe rheumatoid arthritis .</brief_summary>
	<brief_title>Proof-of-Concept Study With BMS-817399 Treat Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female subject , 18 year age old , rheumatoid arthritis ( RA ) least 6 month prior screen Subjects must tender joint count least 6 ( 28 joint count ) , swollen joint count least 6 ( 28 joint count ) screening . All subject must clinical evidence synovitis one hand/wrist screen Serum Creactive protein ( hsCRP ) upper limit normal screening Subjects must treat tolerated Methotrexate ( MTX ) therapy weekly oral parenteral dose ≥ 10 mg ≥ 4 month prior screen . Dose must stable , change route administration , ≥ 6 week prior randomization . A MTX weekly dose low 7.5 mg permit intolerance dos ≥10 mg document subject 's medical history Subjects must receive folic acid , folinic acid , leucovorin supplementation stable dose least 4 week prior randomization Subjects previously treat two tumor necrosis factor α ( TNFα ) inhibitor If take antimalarial ( e.g . hydroxychloroquine chloroquine ) , subject must stable dose ≥ 4 month prior randomization If take nonsteroidal antiinflammatory drug ( NSAIDs ) , subject must stable dos ≥ 2 week prior randomization If take oral corticosteroid , daily dos must ≤ 10 mg/day prednisone equivalent stable ≥ 4 week randomization Subject willing participate study sign informed consent prior undergo screen procedure Women childbearing potential ( WOCBP ) men must agree use least two acceptable method avoid pregnancy entire study period 60 day ( woman ) 90 day ( men ) last dose BMS817399 . WOCBP must negative urine pregnancy test screening , randomization schedule visit throughout study Arthritis onset prior 16 year age subject document juvenile RA Subjects bed wheelchairbound Subjects autoimmune diseases arthritis syndrome Women pregnant , breastfeed positive pregnancy test screen prior randomization Subjects condition could impact upon absorption study drug ( i.e. , gastric stapling , duodenal surgery , malabsorption syndrome ) Subjects history , concurrent severe , progressive , uncontrolled disease ( RA ) opinion investigator might place subject unacceptable risk participation study Subjects present previous ( last 5 year ) malignancy , except history cure squamous basal skin cell carcinoma cure breast cervical cancer Subjects risk tuberculosis ( TB ) evidence TB clinical history , chest X ray tuberculin skin test Subjects evidence active latent bacterial viral infection ( include human immunodeficiency virus ) ; Positive blood screen hepatitis B surface antigen hepatitis C antibody Subjects serious bacterial infection within last 2 month , unless treat resolve antibiotic Subjects clinically significant drug alcohol abuse know cirrhosis include alcoholic cirrhosis If subject receive following treatment , indicate washout period prior randomization must follow : 1 . Oral injectable azathioprine , gold , DPenicillamine , cyclosporine , anakinra , etanercept , parenteral intraarticular corticosteroid : 30 day 2 . Leflunomide : 6 month unless active washout Cholestyramine perform 3 . Mycophenolate mofetil , cyclophosphamide , tacrolimus immunosuppressant : 3 month 4 . Adalimumab , Infliximab , Golimumab , Certolizumab pegol , Abatacept Tocilizumab : 60 day 5 . Rituximab Bcell deplete agent : 1 year Use CYP3A4 inhibitor inducer study Subjects alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 1.5x upper limit normal ( ULN ) , total bilirubin ≥ 1.4x ULN , estimate glomerular filtration rate ( GFR ) &lt; 50 mL/min/1.73m2 , hemoglobin &lt; 10.0 g/dL , white blood cell count &lt; 3,500/mm3 , absolute neutrophil count &lt; 1,700/mm3 platelet &lt; 125,000/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>